Physician profile
Arvind K Sharma
NPI 1588776793
$4,556.55
in general payments reported to CMS, 2019-2025
31 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $85.12 · 2021: $232 · 2022: $693 · 2023: $911 · 2024: $1,178 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $684.44 | 2019-2024 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $636.66 | 2021-2025 | Corevalve Evolut R, Resolute Onyx |
| Amgen INC. | $397.86 | 2019-2025 | Repatha, Repatha |
| Abiomed | $340.13 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $320.41 | 2019-2024 | Xarelto |
| Heartflow, INC. | $256.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $232.23 | 2022-2024 | Camzyos |
| Pfizer INC. | $214.97 | 2019-2025 | |
| Abbott Laboratories | $175.67 | 2024-2025 | Navitor, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $158.55 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $133.03 | 2022-2025 | Leqvio |
| Penumbra, INC. | $127.47 | 2019-2025 | Indigo System |
| Sanofi-Aventis U.S. LLC | $125.32 | 2019-2023 | |
| Medtronic Vascular, INC. | $113.50 | 2019 | |
| Biotronik INC. | $91.43 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $91.31 | 2024 | Inpefa |
| Altathera Pharmaceuticals LLC | $72.68 | 2023 | Sotalol Hydrochloride |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.97 | 2025 | Lifevest |
| Boston Scientific Corporation | $53.54 | 2023-2024 | Watchman Access System, Rotablator Rotational Atherectomy System Console Kit, Watchman Flx |
| Alnylam Pharmaceuticals INC. | $47.38 | 2024-2025 | Amvuttra |
| Cardiva Medical, INC. | $39.41 | 2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Shockwave Medical, INC | $34.61 | 2025 | |
| Novo Nordisk INC | $23.94 | 2022 | |
| Merck Sharp & Dohme LLC | $18.99 | 2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $18.43 | 2024 | Evkeeza |
| Daiichi Sankyo INC. | $18.18 | 2024 | Injectafer |
| Cook Medical LLC | $15.98 | 2019 | |
| Impulse Dynamics (USA) INC. | $15.47 | 2023 | Optimizer |
| Chiesi USA, INC. | $13.88 | 2023 | Kengreal |
| Amarin Pharma, INC. | $13.17 | 2020 | |
| Portola Pharmaceuticals, LLC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.